Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial

Fleissig, 2006, Post-operative arm morbidity and quality of life: results of the ALMANAC randomised trial comparing sentinel node biopsy with standard axillary treatment in the management of patients with early breast cancer, Breast Cancer Res Treat, 95, 279, 10.1007/s10549-005-9025-7

Lucci, 2007, Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011, J Clin Oncol, 25, 3657, 10.1200/JCO.2006.07.4062

Krag, 2007, Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial, Lancet Oncol, 8, 881, 10.1016/S1470-2045(07)70278-4

Krag, 2009, Surgeon training, protocol compliance, and technical outcomes from breast cancer sentinel lymph node randomized trial, J Natl Cancer Inst, 101, 1356, 10.1093/jnci/djp281

Land, 2010, Patient-reported outcomes in sentinel-node negative adjuvant breast cancer patients receiving sentinel-node biopsy or axillary dissection: National Surgical Adjuvant Breast and Bowel Project Phase III Protocol B-32, J Clin Oncol, 10.1200/JCO.2010.28.2491

Ashikaga, 2010, Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection, J Surg Oncol, 102, 111, 10.1002/jso.21535

Efron, 1971, Forcing a sequential experiment to be balanced, Biometrika, 58, 403, 10.1093/biomet/58.3.403

Krag, 2004, NSABP-32: phase III, randomized trial comparing axillary resection with sentinal lymph node dissection: a description of the trial, Ann Surg Oncol, 11, 208S, 10.1245/ASO.2004.11.909

Kaplan, 1958, Nonparametric estimation from incomplete observations, J Am Stat Assoc, 53, 457, 10.1080/01621459.1958.10501452

Cox, 1972, Regression models and life tables (with discussion), J Royal Stat Soc B, 30, 248

Grambsch, 1994, Proportional hazards tests and diagnostics based on weighted residuals, Biometrika, 81, 515, 10.1093/biomet/81.3.515

Gail, 1985, Testing for qualitative interactions between treatment effects and patient subsets, Biometrics, 41, 361, 10.2307/2530862

Gaynor, 1993, On the use of cause-specific failure and conditional failure probabilities: examples from clinical oncology data, J Am Stat Assoc, 88, 400, 10.1080/01621459.1993.10476289

Gray, 1988, A class of K-sample tests for comparing the cumulative incidence of a competing risk, Ann Stat, 16, 1141, 10.1214/aos/1176350951

Freidlin, 2005, Testing treatment effects in the presence of competing risks, Stat Med, 24, 1703, 10.1002/sim.2054

van der Ploeg, 2008, Axillary recurrence after a tumour-negative sentinel node biopsy in breast cancer patients: A systematic review and meta-analysis of the literature, Eur J Surg Oncol, 34, 1277, 10.1016/j.ejso.2008.01.034

Fisher, 1985, Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer, N Engl J Med, 312, 665, 10.1056/NEJM198503143121101

McCahill, 2009, Quality measures for breast cancer surgery: initial validation of feasibility and assessment of variation among surgeons, Arch Surg, 144, 455, 10.1001/archsurg.2009.56

Hopewell, 2010, The quality of reports of randomised trials in 2000 and 2006: comparative study of articles indexed in PubMed, BMJ, 340, c723, 10.1136/bmj.c723

Harlow, 2005, Ann Surg, 241, 48, 10.1097/01.sla.0000149429.39656.94

Olson JA, 2008, Impact of immediate versus delayed axillary node dissection on surgical outcomes in breast cancer patients with positive sentinel nodes: results from American College of Surgeons Oncology Group Trials Z0010 and Z0011, J Clin Oncol, 26, 3530, 10.1200/JCO.2007.15.5630

Veronesi, 2006, Sentinel-lymph-node biopsy as a staging procedure in breast cancer: update of a randomised controlled study, Lancet Oncol, 7, 983, 10.1016/S1470-2045(06)70947-0

Veronesi, 2003, A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer, N Engl J Med, 349, 546, 10.1056/NEJMoa012782

Veronesi, 2010, Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study, Ann Surg, 251, 595, 10.1097/SLA.0b013e3181c0e92a

Mansel, 2006, Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial, J Natl Cancer Inst, 98, 599, 10.1093/jnci/djj158

Gill, 2009, Sentinel-lymph-node-based management or routine axillary clearance? One-year outcomes of sentinel node biopsy versus axillary clearance (SNAC): a randomized controlled surgical trial, Ann Surg Oncol, 16, 266, 10.1245/s10434-008-0229-z

Straver, 2010, Role of axillary clearance after a tumor-positive sentinel node in the administration of adjuvant therapy in early breast cancer, J Clin Oncol, 28, 731, 10.1200/JCO.2008.21.7554

Orr, 1999, The impact of prophylactic axillary node dissection on breast cancer survival—a Bayesian meta-analysis, Ann Surg Oncol, 6, 109, 10.1007/s10434-999-0109-1

Krag, 2003, Breast cancer survival according to number of nodes removed, Ann Surg Oncol, 10, 1, 10.1245/ASO.2003.03.073

Barthelmes, 2010, Adverse reactions to patent blue V dye—the NEW START and ALMANAC experience, Eur J Surg Oncol, 36, 399, 10.1016/j.ejso.2009.10.007

Masannat, 2009, DNA damaging effects of the dyes used in sentinel node biopsy: possible implications for clinical practice, J Surg Res, 154, 234, 10.1016/j.jss.2008.07.039